Interpace Diagnostics Group, Inc. IDXG
We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.
That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).
We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)
Experience Art & Design, Inc. EXAD
We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.
From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.
Catalyst Biosciences, Inc. CBIO
We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.
News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)
Fresh Options Idea: Transocean, Inc. RIG $15 and $14.50 Puts
Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT